“The Company continues to execute at a high level, including recruitment of 143 patients in our ongoing Halneuron Phase 2b trial, commencement of a Phase 2b extension trial and the recent execution of a financing to provide us with operational runway through the Phase 2b final data readout later this year,” said Greg Duncan, CEO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX:
- Dogwood Therapeutics Shareholders Approve Warrant Exercise Proposal
- Dogwood Therapeutics: Strengthened Capital Structure, Advancing Pain Pipeline, and Extended IP Support a Buy-Rated Risk-Reward Profile
- Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
- Dogwood Therapeutics outlines 2026 plans for pain pipeline